search
Back to results

The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study) (BAT)

Primary Purpose

Resistant Hypertension

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
BAT
Placebo
Sponsored by
Helsinki University Central Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Resistant Hypertension

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Eligible patients have a daytime systolic ambulatory blood pressure 145 mmHg or more, and/or a daytime diastolic ambulatory blood pressure of 95 mmHg or more, after witnessed intake of antihypertensive treatment (including at least 3 antihypertensive drugs preferably including a diuretic), with no changes in medication for a minimum of 4 weeks prior to enrolment.

Exclusion Criteria:

  • Patients with secondary causes of hypertension will be excluded.
  • Further exclusion criteria are renal insufficiency with an estimated glomerular filtration rate ≤30 ml/min/1.73 m2 (using the Chronic Kidney Disease Epidemiology [CKD-EPI] formula), untreated sleep apnoea, pregnancy, type 1 diabetes, alcohol or substance abuse or psychiatric illnesses, other heart rhythm than sinus (well controlled atrial fibrillation is not a contraindication), uncontrolled systolic heart failure (or an ejection fraction of less than 40% in echocardiography), aortic stenosis (mean gradient more than 25 mmHg in echocardiography).
  • Myocardial infarction, hypertensive crisis, symptomatic orthostatic hypotension, unstable angina, syncope, or cerebral vascular accident within the 3 months before enrolment will also be exclusion criteria.
  • Furthermore, known or suspected baroreflex failure or autonomic neuropathy, carotid artery stenosis as well as prior surgery, radiation, or endovascular stent placement in the carotid sinus region on both sides, as well as any complication that is a risk to the planned surgery are exclusion criteria.

Sites / Locations

  • Odense University Hospital
  • Helsinki University Central Hospital
  • University of Oslo
  • Sahlgrenska University Hospital, Sweden
  • Skåne University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Baroreflex activation therapy

Placebo

Arm Description

BAT ON

BAT OFF

Outcomes

Primary Outcome Measures

Change in systolic ambulatory blood pressure in response to BAT therapy
Unit: mmHg

Secondary Outcome Measures

Change in systolic ambulatory blood pressure in response to BAT therapy
Unit: mmHg
Change in home/office blood pressure in response to BAT therapy
Unit: mmHg
Change in autonomic function in response to BAT therapy
Unit: ms/mmHg

Full Information

First Posted
October 7, 2015
Last Updated
March 1, 2023
Sponsor
Helsinki University Central Hospital
Collaborators
Odense University Hospital, University of Oslo, University of Helsinki, Sahlgrenska University Hospital, Sweden, Skane University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02572024
Brief Title
The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)
Acronym
BAT
Official Title
The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
November 2015 (undefined)
Primary Completion Date
November 2022 (Actual)
Study Completion Date
March 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Helsinki University Central Hospital
Collaborators
Odense University Hospital, University of Oslo, University of Helsinki, Sahlgrenska University Hospital, Sweden, Skane University Hospital

4. Oversight

5. Study Description

Brief Summary
Resistant hypertension (RH) affects some 10% to 15% of all patients with hypertension. These patients are at a clearly increased risk for end organ damage and mortality. Furthermore, arterial hypertension is a multifactorial disease including genetic, lifestyle, dietary, metabolic, and sympathetic factors. However, the current treatment modalities have not been optimal in targeting the compensatory changes in sympathetic nervous system function and new strategies have been warranted. Baroreflex activation therapy (BAT) is a special treatment option for some patients with RH that modulates the autonomic nervous system to restore sympathovagal balance. Notably, in BAT both long-term safety and efficacy in a large-scale, randomized, double blind, controlled trial has been shown. However, the trial design and BAT methodology resulted in that the first generation Rheos® system did not achieve the prespecified endpoints for short-term safety and efficacy. Notably, a second-generation minimally invasive BAT system (Barostim Neo®) has now been developed to address these limitations although randomized, double blind, controlled clinical trials are still lacking. Noteworthy, in the recent European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines for the management of arterial hypertension, carotid baroreceptor stimulation is mentioned as one of the options to treat resistant hypertension. Based on these data the aim of this randomized, double-blind, parallel-design clinical trial is to examine the effect of BAT compared to continuous pharmacotherapy on blood pressure, as well as arterial and cardiac function and structure using non-invasive high technology methodology, in a Nordic multicentre study. This study will include 100 patients with RH (20 from Helsinki). Eligible patients are between 18 and 70 years and have a daytime systolic ambulatory blood pressure 145 mmHg or more, and/or a daytime diastolic ambulatory blood pressure of 95 mmHg or more, after witnessed intake of antihypertensive treatment (including at least 3 antihypertensive drugs preferably including a diuretic), with no changes in medication for a minimum of 4 weeks prior to enrolment. Patients with severe renal insufficiency, type 1 diabetes, psychiatric illness, severe cardiovascular disease, or any complication that is a risk to the planned surgery are exclusion criteria. The primary end point is to test whether BAT reduces 24-hour systolic ambulatory blood pressure at 8 months of follow-up compared to continuous pharmacotherapy. Secondary end points are to test whether BAT reduces home blood pressure during follow-up compared to continuous pharmacotherapy, whether BAT reduces office blood pressure during follow-up compared to continuous pharmacotherapy, and the effect of BAT on autonomic function measured as eg. baroreflex sensitivity and heart rate variability.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Resistant Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Baroreflex activation therapy
Arm Type
Active Comparator
Arm Description
BAT ON
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
BAT OFF
Intervention Type
Device
Intervention Name(s)
BAT
Intervention Description
Baroreflex activation therapy device ON
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Baroreflex activation therapy device OFF
Primary Outcome Measure Information:
Title
Change in systolic ambulatory blood pressure in response to BAT therapy
Description
Unit: mmHg
Time Frame
8 months
Secondary Outcome Measure Information:
Title
Change in systolic ambulatory blood pressure in response to BAT therapy
Description
Unit: mmHg
Time Frame
19 months
Title
Change in home/office blood pressure in response to BAT therapy
Description
Unit: mmHg
Time Frame
19 months
Title
Change in autonomic function in response to BAT therapy
Description
Unit: ms/mmHg
Time Frame
19 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eligible patients have a daytime systolic ambulatory blood pressure 145 mmHg or more, and/or a daytime diastolic ambulatory blood pressure of 95 mmHg or more, after witnessed intake of antihypertensive treatment (including at least 3 antihypertensive drugs preferably including a diuretic), with no changes in medication for a minimum of 4 weeks prior to enrolment. Exclusion Criteria: Patients with secondary causes of hypertension will be excluded. Further exclusion criteria are renal insufficiency with an estimated glomerular filtration rate ≤30 ml/min/1.73 m2 (using the Chronic Kidney Disease Epidemiology [CKD-EPI] formula), untreated sleep apnoea, pregnancy, type 1 diabetes, alcohol or substance abuse or psychiatric illnesses, other heart rhythm than sinus (well controlled atrial fibrillation is not a contraindication), uncontrolled systolic heart failure (or an ejection fraction of less than 40% in echocardiography), aortic stenosis (mean gradient more than 25 mmHg in echocardiography). Myocardial infarction, hypertensive crisis, symptomatic orthostatic hypotension, unstable angina, syncope, or cerebral vascular accident within the 3 months before enrolment will also be exclusion criteria. Furthermore, known or suspected baroreflex failure or autonomic neuropathy, carotid artery stenosis as well as prior surgery, radiation, or endovascular stent placement in the carotid sinus region on both sides, as well as any complication that is a risk to the planned surgery are exclusion criteria.
Facility Information:
Facility Name
Odense University Hospital
City
Odense
Country
Denmark
Facility Name
Helsinki University Central Hospital
City
Helsinki
Country
Finland
Facility Name
University of Oslo
City
Oslo
Country
Norway
Facility Name
Sahlgrenska University Hospital, Sweden
City
Göteborg
Country
Sweden
Facility Name
Skåne University Hospital
City
Malmö
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)

We'll reach out to this number within 24 hrs